When will Ocriplasmin be launched in the Chinese market?

Ocriplasmin (Ocriplasmin) was first developed by ThromboGenics and approved for marketing in Europe and the United States under the trade name Jetrea. It is used to treat symptomatic vitreomacular traction (VMT) and some macular holes. After being launched in Europe and the United States, this drug has received some attention due to its non-surgical method, but market acceptance varies due to price and indication restrictions. For the Chinese market, the introduction time of Oak plasmin has always been the focus of clinical and patient groups.

Currently, according to the public information from the National Medical Products Administration (NMPA), Oak Plasmin has not yet entered the large-scale marketing stage. Although some data show that there have been applications for registration of imported drugs, the progress has not been as rapid as other innovative ophthalmic drugs. This is closely related to the domestic market environment, patient needs, medical insurance policies and corporate business decisions. For multinational pharmaceutical companies, the Chinese market has huge potential, but the drugs have narrow indications and strict patient screening, resulting in considerable challenges in their marketing.

It is worth noting that in recent years, my country has increased policy support for the treatment of fundus diseases, especially the national centralized procurement and rapid review mechanisms for imported innovative drugs that have gradually matured, which provides a possible policy channel for Oak plasmin to enter the Chinese market. As the level of ophthalmology diagnosis and treatment in China is in line with international standards, the early diagnosis rate of macular diseases has gradually increased, and clinicians' demand for innovative drugs has increased. Therefore, it is generally expected in the industry that Oak Plasmin is expected to enter the domestic market through accelerated review channels in the next few years. Although the exact launch time has not been made public, what is certain is that with the promotion of market demand and policy guidance, it is only a matter of time before it enters China.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html